Zevra Therapeutics (NASDAQ:ZVRA) Price Target Increased to $18.00 by Analysts at HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA) had its price target hoisted by HC Wainwright from $15.00 to $18.00 in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2025 earnings at $0.26 EPS and FY2028 earnings at $3.12 EPS.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA remained flat at $7.88 during mid-day trading on Monday. The company had a trading volume of 1,443,028 shares, compared to its average volume of 376,750. The firm has a market cap of $329.80 million, a PE ratio of -5.92 and a beta of 1.97. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.44. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.88. The firm’s 50 day simple moving average is $5.19 and its 200 day simple moving average is $5.43.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. The business had revenue of $3.43 million for the quarter, compared to the consensus estimate of $3.52 million. Zevra Therapeutics had a negative return on equity of 82.55% and a negative net margin of 181.76%. Equities analysts forecast that Zevra Therapeutics will post -1.57 earnings per share for the current year.

Insider Activity at Zevra Therapeutics

In other news, Director Thomas Anderson purchased 10,000 shares of the stock in a transaction dated Tuesday, July 16th. The shares were bought at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the transaction, the director now owns 20,000 shares in the company, valued at $136,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 22,000 shares of company stock worth $140,340 in the last three months. 2.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently modified their holdings of ZVRA. International Assets Investment Management LLC increased its position in shares of Zevra Therapeutics by 555.0% during the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock valued at $43,000 after purchasing an additional 5,550 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Zevra Therapeutics by 134.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock worth $63,000 after acquiring an additional 5,545 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics in the 1st quarter worth $64,000. IFG Advisors LLC grew its holdings in shares of Zevra Therapeutics by 45.0% in the 1st quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after acquiring an additional 5,800 shares during the last quarter. Finally, Strs Ohio grew its holdings in shares of Zevra Therapeutics by 151.9% in the 4th quarter. Strs Ohio now owns 19,400 shares of the company’s stock worth $127,000 after acquiring an additional 11,700 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.